Osteoporosis, inflammation and ageing.
Ginaldi L, Di Benedetto MC, De Martinis M. · 2005
Read Osteoporosis, inflammation and ageing. by Ginaldi L, Di Benedetto MC, De Martinis M. (2005) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc1308846.txt.
Introduction
Ginaldi, Di Benedetto, and De Martinis reviewed osteoporosis through inflammation and aging in 2005. Osteoporosis thins bones and raises fracture risk in older people. Hormones, metabolism, and mechanics were the classic explanations. New evidence adds chronic inflammation as a driver.
Inflammatory signaling molecules regulate both bone-building and bone-eating cells. Aging remodels the immune system toward a more activated profile. That shift may tip bone turnover toward loss. Conditions linked to osteoporosis often share chronic inflammation too. Ginaldi reads osteoporosis partly as an inflamed aging disease. Bone loss in old age is the core concern. Old age is when the risk is at its peak for most men and women. Falls and breaks are the main harm that comes from thin bones.
Catalog record
| CREATOR | Ginaldi L, Di Benedetto MC, De Martinis M. |
|---|---|
| YEAR | 2005 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Osteoporosis, inflammation and ageing By Lia Ginaldi, Maria Cristina Di Benedetto, Massimo De Martinis Published in: Immunity & ageing : I & A DOI: 10.1186/1742-4933-2-14 ABSTRACT Abstract Osteoporosis is a condition characterized by low bone mass and increased bone fragility, putting patients at risk of fractures, which are major causes of morbidity substantially in older people. Osteoporosis is currently attributed to various endocrine, metabolic and mechanical factors. However, emerging clinical and molecular evidence suggests that inflammation also exerts significant influence on bone turnover, inducing osteoporosis. Numerous proinflammatory cytokines have been implicated in the regulation of osteoblasts and osteoclasts, and a shift towards an activated immune profile has been hypothesized as important risk factor. Chronic inflammation and the immune system remodelling characteristic of ageing, as well as of other pathological conditions commonly associated with osteoporosis, may be determinant pathogenetic factors. The present article will review the current perspectives on the interaction between bone and immune system in the elderly, providing an interpretation of osteoporosis in the light of inflamm-ageing. Keywords: Ageing, Inflammation, Cytokines, Bone remodelling, Osteoporosis INTRODUCTION Osteoporosis is a relevant age related disorder, characterized by low bone mass and increased bone fragility putting the patient at risk for fractures [1]. Currently osteoporosis is viewed as a heterogeneous condition which can occur in any age of life and its etiology is attributed to various endocrine, metabolic and mechanical factors (abnormalities of parathyroid hormone and calcitonin secretion, insufficient vitamin D and calcium intake, postmenopausal hormonal condition, pregnancy, nutritional disorders, immobility and consumption of drugs such as cortisone, among others) [2]. Recently, growing understanding of the bone remodelling process suggests that factors involved in inflammation are linked with those critical for bone physiology and remodelling, supporting the theory that inflammation significantly contributes to the aetiopathogenesis of osteoporosis [3,4]. IS OSTEOPOROSIS AN INFLAMMATORY PROCESS? Clinical observations reveal coincidence of systemic osteoporosis with period of systemic inflammation as well as co-localization of regional osteoporosis with areas of regional inflammation [2]. Different epidemiologic studies report an increase in the risk of developing osteoporosis in various inflammatory conditions [5-8]. Immunological dysfunctions, autoimmune and chronic inflammatory diseases [9], HIV infection [10], hyper-IgE syndrome [11], rheumatoid arthritis [12], haematological diseases, particularly myeloma [13], and inflammatory bowel diseases [14], are associated with osteoporosis. Erosions seen in conditions such as gout, osteomyelitis, rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis, are typically associated with inflammation in the joints. Pro-osteoclastic cytokines, such as tumour necrosis factor (TNF)-α and interleukin (IL)-6, are elevated in these conditions and local cytokine profile is consistent with the cytokines that modulate bone resorption [15,16]. C-reactive protein (CRP) production in the liver is upregulated by IL-1, IL-6 and TNF-α, and is regarded as a sensitive marker of systemic inflammation [17,18]. An association between circulating high sensitive (hs)CRP level and bone mineral density has been observed in several immune and inflammatory diseases, as well as in healthy individuals, suggesting a relationship between subclinical systemic inflammation and osteoporosis [19]. Rheumatoid arthritis (RA) is a typical example of the link between inflammation and osteoporosis. Bone loss in RA occurs both in the joints and throughout the skeleton as a result of the release of proteinases (metalloproteinases) and proinflammatory cytokines (IL-1, TNF-α), which are responsible for cartilage and bone destruction. As a result, disease activity is an independent risk factor for osteoporosis in RA [20]. A temporal link between inflammation and osteoporosis also emerges in conditions such as ageing, menopause, pregnancy, transplantation and steroid administration. While nutritional, mechanical and hormonal factors clearly play a role in many of these situations, the concordance of osteoporosis and inflammation is buttressed by emerging molecular evidence of mediating immunological factors [2]. On the other hand, one intriguing aspect of immunosenescence is the increased production of pro-inflammatory cytokines with age and a close link between age-related systemic inflammatory process (inflamm-ageing)[21] and osteoporosis is well documented [22]. A MOLECULAR SCENARIO OF IMMUNE REGULATED BONE LOSS Although osteoporosis is not typically considered an immunological disorder, recent data have indicated overlapping pathways between bone biology and biology of inflammation [23-25]. Certain pro-inflammatory cytokines play potential critical roles both in the normal bone remodelling process and in the pathogenesis of perimenopausal and late-life osteoporosis [26]. For example, interleukin (IL)-6 promotes osteoclast differentiation and activation [27]. This cytokine is involved in the pathogenesis of various metabolic bone diseases, including postmenopausal osteoporosis, Paget's disease and osteoporosis associated with heamtologic malignancies [28]. IL-1 is another potent stimulator of bone resorption [29] that has been linked to the accelerated bone loss seen in idiopathic and postmenopausal osteoporosis [30]. TNF-α is implicated in tumour-induced bone resorption and non-tumour-induced osteopenia [31]. Anti-TNF drugs, currently used in the therapy of several immunological disorders, are also useful in preventing and/or reversing systemic bone loss associated to the disease, as they target both the bone and the inflammatory process [20]. The production of IL-1, IL-6, and/or TNF-α by peripheral blood monocytes has been positively correlated with bone resorption or spinal bone loss in healthy pre- and postmenopausal women [32]. The inflammatory mediator nitric oxide (NO) is also involved in the pathogenesis of osteoporosis. The activation of the inducible NO synthesis (iNOS) pathway by cytokines, such as IL-1 and TNF-α, inhibits osteoblast function in vitro and stimulates osteoblast apoptosis [33]. The TNF-family molecule RANKL and its receptor RANK (receptor activator of NFkB ligand) have been specifically implicated in the bone loss in rheumatoid arthritis [34]. They are key regulators of bone remodelling and are essential for the development and activation of osteoclasts. Intriguingly, RANKL/RANK interactions also regulate T cell/dendritic cell communication, dendritic cell survival and lymphnode formation [35]. Calciotropic factors such as vitamin D3, PGE2, IL-1, IL-11, TNF-α and glucocorticoid induce RANKL expression on osteoblasts [36]. RANKL binding to the RANK expressed on haematopoietic progenitors activates a signal transduction cascade that leads to osteoclast differentiation. Moreover, RANKL stimulates bone resorbing activity in mature osteoclasts via RANK. When RANK is activated, it sends signals into the cells through tumor necrosis factor receptor-associated factors (TRAFs), mainly TRAF6. These RANK associated molecules, through downstream pathways such as NF-kB, JNK/SAPK, p38 and Akt/PKB, regulate bone resorption, activation, survival, and differentiation of osteoclasts and dendritic cells. Osteoprotegerin (OPG), also known as osteoclastogenesis inhibitory factor, functions as a soluble decoy receptor to RANKL and competes with RANK for RANKL binding. TGFβ released from bone during active bone resorption has been suggested as a feedback mechanism by upregulating OPG level. Estrogen can enhance OPG production on osteoblasts which is a possible explanation of postmenopausal osteoporosis following estrogen withdrawal [35]. Since the expression of RANKL/RANK can be controlled by sex hormones, it is possible to speculate that this system may control gender specific differences in immunity and could be involved in the higher incidence of autoimmune diseases and osteoporosis in women. RANK-L, RANK and OPG therefore configure interesting molecular links between bone remodelling, immunity and inflammation. THE EMERGENCE OF OSTEOIMMUNOLOGY There exists an intimate interplay between the bone and the immune system which has been termed osteoimmunology [3]. The activity of immune cells affects the balance of bone mineralization and resorption carried out by the opposing actions of osteoblasts and osteoclasts [37]. Dendritic cells, specialized to present antigens, and osteoclasts, specialized to resorb bone, share the same bone marrow precursors